Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TECOS sitagliptin cardiovascular outcomes trial in type 2 diabetes
2008-006719-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Started Feb 2009; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006719-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006719-20.